Despite significant developments in managing type 2 diabetes (T2D), many patients will ultimately require basal insulin. The challenge lies not solely in initiating insulin therapy but also in optimizing it. Over-reliance on basal insulins can lead to unnecessary treatment burdens. Once-weekly basal insulin formulations signify a major advancement, potentially simplifying the regimen for many patients.
Discussions regarding insulin often arise later than optimal. A prevalent misconception is that adding insulin indicates failure. Such views do not align with the understanding that T2D is progressive; over time, beta-cell function wanes. The UKPDS 49 study illustrates this, showing only about 25% of participants retained an A1C below 7% after nine years with monotherapy, necessitating a tailored treatment approach.
Today's treatment algorithms prioritize not just glycemic control but also address cardiovascular risks and metabolic comorbidities. Current guidelines recommend initiating treatments like GLP-1 receptor agonists or dual agonists before considering insulin for most adults without severe hyperglycemia. Basal insulin administration remains essential as it effectively reduces hepatic glucose release overnight and in between meals, aligning with the patient's glycemic targets.
Indications for basal insulin commencement include cases where glycemic goals remain unmet despite appropriate noninsulin therapy adherence and lifestyle modifications. Symptoms such as hyperglycemia, weight loss, or ketosis demand more immediate insulin intervention. According to the 2026 ADA Standards, symptomatic hyperglycemia, A1C >10%, or glucose levels of ≥300 mg/dL justify insulin initiation, regardless of the patient's diabetes duration.
In patients not facing severe hyperglycemia, the approach to insulin therapy becomes personalized. Despite effective treatment with metformin, GLP-1 receptor agonists, or SGLT2 inhibitors, some individuals will still exceed their target A1C due to declining endogenous insulin production. Adding basal insulin under these circumstances represents not a regression but a strategic enhancement to address progressive beta-cell insufficiency. Importantly, current guidelines advocate for concurrently preserving other agents that prove effective against cardiovascular or renal risk when clinically appropriate, while reevaluating those that may increase hypoglycemia risk without contributing meaningful therapeutic benefits.
A practical approach involves reshaping conversations around insulin therapy, framing it not as finality but as a valuable tool. This includes defining the role of basal insulin, outlining individualized glucose targets, discussing the monitoring plan, and establishing protocols for recognizing and managing hypoglycemia. Furthermore, clinicians should ensure discussions factor in the practical aspects of basal insulin options, like dosing frequency, device specifics, and additional patient support, thereby encouraging a collaborative decision-making process.
The evolution of basal insulin has led to predictable glucose lowering via long-acting analogs. Once-weekly formulations stretch this innovation, reducing necessary injections from daily to weekly. For some patients, this decrease in injection frequency may be appealing. However, assuming reduced dosing frequency will universally improve adherence and outcomes is risky. Missing a weekly dose may carry different implications compared to missing a daily dose; the sustained action of these formulations necessitates precision in dosing, monitoring, and patient education.
Clinical trials assessing once-weekly insulins, like insulin efsitora alfa and insulin icodec, have largely demonstrated A1C reductions that are comparable to traditional daily dosing, with some analyses favoring the weekly regimen slightly. A systematic review encompassing 14 trials involving almost 8,500 T2D adults yielded minor A1C advantages and improved time-in-range metrics for weekly therapies, although hypoglycemia occurrences did not differ significantly at class level. Treatment efficacy varies by specific formulation and trial design; thus, distinguishing these factors remains crucial.
Evidence from early-phase studies also examined safety outcomes during unique scenarios of increased insulin needs, such as during fasting or exercise. Most hypoglycemic events reported were minor, underscoring the tolerability of once-weekly insulins, which may provide meaningful advantages for appropriately selected adults with T2D while enhancing their treatment experience through fewer injections.
Exercise impacts glucose levels, necessitating proactive patient education around monitoring and adjustments to their regimen when physical activity changes. Clinicians should advocate for increased glucose checks and establish plans for addressing potential hypoglycemia. Observations from studies on once-weekly insulins reveal no consistent hypoglycemic risks tied to increased physical activity compared to daily insulins, though individualized precautions remain essential.
Fasting or surgical procedures require meticulous planning, including documentation of the last dose and anticipated schedule. This allows effective coordination with healthcare teams while maintaining patient safety. Given the extended action of weekly formulations, the effects of missed doses need serious consideration, particularly against a background of unique physiologic responses seen in fasting scenarios. Clinicians must remain vigilant, monitoring glucose levels closely post-injection, reinforcing the importance of a rescue plan for blood glucose fluctuations.
Acute illnesses present further challenges, influencing insulin requirements and necessitating tailored monitoring strategies. These instances demand careful patient instruction regarding when and how to reach out to their care teams, ensuring effective management in fluctuating conditions.